Back to search

Article

Pseudocannabinoid H4CBD enhances lipid catabolism to reduce visceral adiposity and large adipocyte size in advanced metabolic syndrome

2025-08-19

Abstract excerpt

<title>Abstract</title> <p> Background Metabolic Syndrome (MetS) is a precursor for cardiovascular disease (CVD) and type 2 diabetes (T2D) and has a prevalence of 55% among people ≥ 60 years of age in the US. Cannabidiol (CBD) use has grown more popular in the last two decades, particularly amongst adults > 55 years of age. Synthetic analogues of CBD have generated great interest because they can offer safer, ch...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cf02cfbd-2f27-52f2-aad6-db2960b1627e
DOI
10.21203/rs.3.rs-7274449/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pseudocannabinoid H4CBD enhances lipid catabolism to reduce visceral adiposity and large adipocyte size in advanced metabolic syndromeDOI 10.21203/rs.3.rs-7274449/v1
Select a neighboring publication to make it the new centre.